The conversation is about the potential of SCUBE3 to regrow a juvenile hairline. Specific treatments mentioned include Minoxidil, Finasteride, and RU58841.
Male pattern baldness (MPB) may be an early warning sign for type 2 diabetes due to its association with insulin resistance. Treatments discussed include testosterone therapy and finasteride, which affects hormone levels related to hair loss and insulin sensitivity.
The user has been using 1mg finasteride daily, 2.5mg minoxidil daily, topical tretinoin three times a week, and topical minoxidil daily from June 2023 to June 2025 without noticeable improvement in hair loss. Suggestions include switching to dutasteride and increasing oral minoxidil to 5mg daily, but concerns about long-term health effects are raised.
The user experienced better hair thickening results with a combination pill of oral minoxidil (3mg) and finasteride (1mg) compared to previous treatments with topical minoxidil and finasteride alone. They reported no significant side effects and expressed regret for not starting this treatment earlier.
Users discussed hair loss treatments, specifically 0.1% latanoprost with melatonin, caffeine, and biotin. Other treatments mentioned include minoxidil, finasteride, RU58841, and microneedling.
The conversation discusses concerns that Minoxidil may cause skin aging, like collagen depletion and puffier faces. Some users suggest that a good skincare routine or collagen supplements might prevent these effects.
Veradermics' new hair loss treatment, VDPHL01, is likely a modified release oral minoxidil, which has received $75 million in funding for clinical trials. Despite skepticism about investing in a known treatment, some believe it could offer improved efficacy and reduced side effects.
A user reported significant facial aging after using minoxidil for hair loss, despite a good skincare routine and healthy lifestyle. They plan to switch to dutasteride and possibly stop minoxidil.
Oral minoxidil may cause facial bloating and dark circles, making some users feel they look older. Some consider reducing the dosage or switching treatments due to these side effects.
A 20-year-old is experiencing severe diffuse thinning and shedding despite using oral minoxidil for 12 months and dutasteride for 8 months, after previously trying finasteride. They are frustrated with the lack of improvement and considering trying RU58841.
A person in their early 30s has been using finasteride for about 10 years and recently started oral minoxidil, vitamin chewables, and dermarolling to address hair loss. They noticed pigmented vellus hairs and potential regrowth, questioning if oral minoxidil is more effective than topical due to enzyme differences.
A 20-year-old user experienced worsening hair loss despite using various treatments including topical and oral minoxidil, finasteride, and dutasteride. Other users suggested additional treatments like JAK inhibitors, RU58841, and lifestyle changes, but the user remains skeptical and frustrated.
Amplifica has not provided updates on SCUBE3 and AMP-303, raising concerns about their trial outcomes. Users also mention other treatments like Minoxidil, finasteride, RU58841, PP405, and ET-03.
A 56-year-old user shared progress pictures from January to June 2024, detailing their hair loss treatment journey. They used Nanoxidil, oral Minoxidil, Finasteride (later switched to Dutasteride), RU58841, and LLLT therapy, noting slow but visible improvements.
A 19-year-old male experienced significant hair loss, initially thought to be male pattern baldness (MPB), and used minoxidil and briefly finasteride. After realizing the issue was telogen effluvium (TE), he improved his diet and supplemented with vitamins, which led to substantial hair regrowth.
A user's father experienced hair regrowth and other health improvements after two IV exosome treatments. The user also had four rounds of exosome therapy, noting significant hair regrowth and relief from headaches, but no change in gray hair.
A 24-year-old is experiencing hair shedding and regrowth while using dutasteride (1mg), vitamin D, and minoxidil (5%). Others share similar experiences with hair loss treatments like minoxidil and finasteride.
A 21-year-old male diagnosed with telogen effluvium and male pattern baldness started taking finasteride, which initially slowed hair shedding and slightly thickened hair. The doctor recommended iron and vitamin D supplements, and the user is considering minoxidil but wants to stabilize shedding first.
The user is experiencing increased hair shedding and is concerned about regression despite consistent use of finasteride, minoxidil, and other treatments. The consensus is that this is likely a temporary shedding phase, and adjustments to the dermarolling frequency are suggested.
A 31-year-old uses Minoxidil, RU58841, Reviv Hair Serum, and Ketoconazole shampoo for hair loss but avoids finasteride. They plan to reintroduce red light therapy (LLLT) and Eucapil despite previous shedding concerns.
A user is experiencing hair regrowth after treating vitamin D, B12, and B9 deficiencies, noticing some improvement after 9 months. They are unsure if further improvement will occur or if they have reached the end of progress, with a possibility of androgenetic alopecia (AGA) being suggested.
PTD-DBM is being explored for hair regrowth by targeting CXXC5, with clinical trials expected after pre-clinical studies. Users express anticipation and skepticism about its effectiveness.
The user increased their steroid dosage and noticed hair shedding, so they adjusted their regimen by reducing steroid doses and adding oral dutasteride. They are also experimenting with combining RU-58841 and KX-826/pyrilutamide in minoxidil to address hair loss.
The conversation discusses the use of low-dose oral minoxidil for hair loss and its potential effects on skin aging. Users shared experiences, with some noting side effects like puffy eyelids and dark circles, but no conclusive evidence of significant collagen depletion or increased wrinkles.
A 22-year-old male uses dutasteride, a serum with 10% minoxidil and 0.5% finasteride, and microneedling for diffuse androgenetic alopecia. Progress pictures show changes from July 2025 to February 2026.
PP405 shows promise for hair regrowth by manipulating stem cell characteristics and lactate dehydrogenase, with Phase 2a trials pending. Google Ventures' $15M investment suggests confidence, but results and market availability remain uncertain.
miR-205, a tiny RNA, can stimulate hair growth by softening aging hair follicle stem cells in mice. Future tests aim to see if this can work in humans.
A user's two month update on their hair loss journey and the treatments they are trying, which include exosome injections, minoxidil, finasteride, and RU58841.